Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADINASDAQ:AIMDNASDAQ:CELUNASDAQ:DTIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.99+5.9%$1.80$1.21▼$3.81$49.15M0.68253,080 shs57,482 shsAIMDAinos$3.29+3.1%$2.80$2.00▼$5.00$13.79M2.1372,590 shs59,999 shsCELUCelularity$2.05+1.0%$1.93$1.00▼$5.22$47.42M0.74338,543 shs20,385 shsDTILPrecision BioSciences$4.38+2.7%$4.89$3.61▼$11.09$48.12M1.43224,058 shs61,346 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+1.08%-0.53%+8.05%+14.63%+34.29%AIMDAinos+3.13%+36.46%+2.11%+25.33%-30.00%CELUCelularity+0.99%+7.33%-11.64%+48.55%-34.29%DTILPrecision BioSciences+2.70%+5.68%-15.05%-5.10%-52.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.6606 of 5 stars1.00.00.00.01.12.51.3AIMDAinos0.8361 of 5 stars0.04.00.00.00.81.70.6CELUCelularity0.1769 of 5 stars0.01.00.00.01.91.70.0DTILPrecision BioSciences4.5193 of 5 stars3.53.00.04.62.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-16.25% DownsideAIMDAinos 0.00N/AN/AN/ACELUCelularity 0.00N/AN/AN/ADTILPrecision BioSciences 3.00Buy$47.00974.29% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, CELU, DTIL, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.96N/AN/A$4.29 per share0.46AIMDAinos$20K689.26N/AN/A$5.51 per share0.60CELUCelularity$54.22M0.91N/AN/A$0.37 per share5.54DTILPrecision BioSciences$68.70M0.71N/AN/A$6.87 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)AIMDAinos-$14.86M-$1.29N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)CELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%7/28/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)Latest AIMD, CELU, DTIL, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/12/2025Q1 2025AIMDAinosN/A-$1.05N/A-$0.21N/A$0.11 million5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AAIMDAinosN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54AIMDAinos0.842.001.91CELUCelularity4.070.380.28DTILPrecision BioSciences0.456.626.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%AIMDAinosN/ACELUCelularity19.02%DTILPrecision BioSciences37.99%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%AIMDAinos10.39%CELUCelularity22.10%DTILPrecision BioSciences4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableAIMDAinos404.19 million3.76 millionNot OptionableCELUCelularity22023.95 million18.66 millionOptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataAIMD, CELU, DTIL, and AADI HeadlinesRecent News About These CompaniesRevelyst Appoints Innovation Chief at Precision Sports TechnologyJuly 2 at 5:04 PM | sgbonline.comSChina’s Dongshan Precision moves to buy Taiwan’s Source Photonics, triggering tech security alarmsJuly 2 at 5:04 PM | digitimes.comDTransDigm to acquire Simmonds Precision Products for about $765 millionJune 30, 2025 | kalkinemedia.comKTransDigm to Buy Simmonds Precision Products From RTX for $765 MillionJune 30, 2025 | marketwatch.comHogge Precision Reinforces Leadership in Medical CNC Machining with Advanced Capabilities and Industry ExpertiseJune 30, 2025 | palmbeachpost.comPFounder of Neuralink rival Precision Neuroscience reveals what people often get wrong about brain-implant surgeryJune 29, 2025 | msn.comPrecision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - MorningstarJune 26, 2025 | morningstar.comMDTIL - Precision BioSciences Inc Key Metrics - MorningstarJune 26, 2025 | morningstar.comMPrecision BioSciences Gets FDA's Rare Pediatric Disease Designation For PBGENE-DMD - NasdaqJune 26, 2025 | nasdaq.comDTIL Precision BioSciences, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPrecision’s gene-editing therapy gets FDA’s rare pediatric disease statusJune 26, 2025 | musculardystrophynews.comMPrecision BioSciences Gains FDA Rare Pediatric Disease Designation for PBGENE-DMDJune 25, 2025 | contractpharma.comCPrecision BioSciences stock jumps after FDA grants rare pediatric designationJune 25, 2025 | za.investing.comPrecision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyJune 25, 2025 | businesswire.comNeuralink Co-founder Tapped by Rival Precision NeuroscienceJune 12, 2025 | theinformation.comTPrecision Neuroscience adds Neuralink co-founder, former FDA director to leadership teamJune 12, 2025 | massdevice.comWhat’s Next for Cancer Precision Medicine?June 10, 2025 | technologynetworks.comT46,929 Shares in Precision BioSciences, Inc. (NASDAQ:DTIL) Purchased by Squarepoint Ops LLCJune 9, 2025 | marketbeat.comPrecision medicine’s next frontier: unlocking the power of biospecimensJune 2, 2025 | fiercebiotech.comFUncovering Potential: Precision BioSciences's Earnings PreviewMay 16, 2025 | benzinga.comPrecision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, CELU, DTIL, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.99 +0.11 (+5.85%) As of 07/3/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Ainos NASDAQ:AIMD$3.29 +0.10 (+3.13%) As of 07/3/2025 01:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Celularity NASDAQ:CELU$2.05 +0.02 (+0.99%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$2.01 -0.04 (-1.95%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Precision BioSciences NASDAQ:DTIL$4.38 +0.12 (+2.70%) Closing price 07/3/2025 03:21 PM EasternExtended Trading$4.36 -0.01 (-0.23%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
